Long-Arg 3
Introduction
Long-Arg 3 -insulin-like growth factor-I (LR 3 IGF-I) is an 83 amino acid (M r 9110) analog of human IGF-I (70 amino acids, M r 7500) comprising the complete IGF-I sequence except for the substitution of arginine for glutamate at position 3 in the wild type IGF-I sequence and for the addition of a 13 amino acid peptide extension at the amino terminus . LR 3 IGF-I binds mitogenic Type 1 IGF receptors with slightly lower affinity than authentic IGF-I and binds to IGF-binding proteins very poorly , Ballard et al. 1993 . LR 3 IGF-I is more potent than native IGFs-I and -II in its ability to stimulate synthesis of protein and DNA and inhibit protein breakdown in cultured rat L6 myoblasts ) and many other cell types. It is also generally more effective than IGFs-I and -II in promoting growth in vivo in rats (Ballard et al. 1991 , Tomas et al. 1992 , 1993a . LR 3 IGF-I is also pharmacologically active in nonrodent species. For example, intravenous infusion of LR 3 IGF-I into fed pigs or fasted cows acutely reduces concentrations of glucose and amino acids in blood and subcutaneous infusion of LR 3 IGF-I into normal guinea pigs chronically increases the weight of several visceral organs (Conlon et al. 1995) . The higher potency of LR 3 IGF-I compared with wild type IGFs appears to be due to its much lower affinity for IGF-binding proteins, despite the slightly lower affinity of LR 3 IGF-I for Type 1 IGF receptors. IGF-binding proteins are produced by most cultured mammalian cells, are present in blood, lymph and other biological fluids and have diverse effects on IGF action (Rechler 1995) . Under certain conditions, these binding proteins can reduce the in vitro cellular response to IGFs by inhibiting IGF binding to cell surface membraneassociated Type 1 IGF receptors .
IGF-binding proteins can also increase, enhance or potentiate the in vitro actions of IGFs by increasing their bioavailability through protection from proteolytic inactivation or by sequestering them in the extracellular matrix or on the cell membrane which may increase their access to cell surface receptors (Rechler 1995) . In vivo studies of IGF analogs with defined differences in affinities for binding proteins have proven useful in defining the roles of IGF receptors and IGF-binding proteins in the physiology, pathology and pharmacology of IGF action. Analytical discrimination between the concentrations of endogenous IGF-I, IGF-II and IGF analogs in biological fluids can contribute significantly to such investigations. The current procedure for measurement of LR 3 IGF-I in biological fluids from animals treated with this peptide is RIA (Conlon et al. 1995) . Despite the low affinity of LR 3 IGF-I for IGF-binding proteins, these binding proteins interfere in the LR 3 IGF-I RIA in much the same way as they do in RIAs for IGFs-I and -II unless they are removed prior to assay (Daughaday et al. 1987 , Breier et al. 1991 . The preferred method for achieving this is chromatographic extraction under acidic, dissociating conditions before RIA (Hintz & Liu 1977 , Powell et al. 1986 , Daughaday et al. 1987 , Breier et al. 1991 , Crawford et al. 1992 ). Here we describe the development, performance and characteristics of a nonisotopic assay of LR 3 IGF-I in blood plasma that does not require sample extraction.
Materials and Methods

Animals and reagents
All animal procedures were carried out in accordance with the guidelines of the National Health and Medical Research Council of Australia. Antibody production in mice was approved by the Animal Ethics Committee of the University of Adelaide. Antibody production in rabbits was approved by the Animal Experimentation and Ethics Committee of the CSIRO Division of Human Nutrition. 
Preparation of antibodies
Female BALB/C mice, aged 6 weeks, were immunised intraperitoneally with ovalbumin conjugated to a mixture of IGF-I and LR 3 IGF-I (molar ratio of IGF-I:LR 3 IGF-I:ovalbumin, 1:1:4). Isolated mouse spleen cells were fused with SP2/Ø-Ag14 (SP2/Ø) mouse myeloma cells (ratio of 5:1 spleen cells:SP2/Ø cells) in the presence of 50% (wt/vol) PEG 1500 (modified from Oi & Herzenberg 1980) . Hybridoma cells were selected by culturing in medium DMEM/F12 containing 1 µg/ml azaserine, 13·6 µg/ml hypoxanthine, 150 µg/ml oxalacetic acid, 20 µg/ml insulin and 20% FCS for 2 weeks and cultures were propagated in the same medium without azaserine. All hybridoma cultures produced mouse immunoglobulins. Cultures were propagated and screened for production of anti-IGF immunoglobulins. Conditioned media from 50 of the 471 cultures contained antibodies that reacted either with plates coated with LR 3 IGF-I or with [ 125 I]-LR 3 IGF-I in solution (see below). Based on the strength of these reactions 19 of these 50 cultures were selected for cloning and eight stable clones were established. These were injected intraperitoneally into pristane (2,6,10,14-tetramethylpentadecane) primed BALB/C mice for production of mouse monoclonal antibodies in ascites fluid. Rabbit anti-IGF immunoglobulins were prepared by immunising New Zealand White rabbits subcutaneously with ovalbumin conjugated either to LR 3 IGF-I or IGF-I (Francis et al. 1989) . Immunoglobulins were precipitated from Nelson antiserum with saturated ammonium sulphate (Goding 1983) .
Characterisation of antibodies
Immunoglobulin types were identified with the mouse typer isotyping panel (BIO-RAD, Richmond, CA, USA). Specificities of antibodies in culture supernatants from hybridoma clones were initially assessed by comparing their abilities to bind to microtitre plates coated with IGF-I, IGF-II and LR 3 IGF-I and to bind [ 125 I]-LR 3 IGF-I in solution. For the solid phase assay, microtitre 96-well plates were coated for 4 h at 37 C with 100 µl IGF-I, IGF-II or LR 3 IGF-I at 2·5 and 0 µg/ml in 50 mmol/l carbonate buffer pH 9·6 for 4 h at 37 C (coating buffer). Plates were washed four times with 1·5 mmol/l KH 2 PO 4 , 6·5 mmol/l Na 2 HPO 4 and 500 mmol/l NaCl containing 0·05% (vol/vol) Tween 20 (PBS-Tween 20), blocked by incubation at 4 C overnight with 100 µl 10 mg/ml BSA in PBS-Tween 20 and again washed as above. A total of 100 µl hybridoma culture supernatant were added to each well and incubated for 3 h at 37 C. After washing as above, captured hybridoma antibodies were detected after addition of 100 µl peroxidase-conjugated rabbit antimouse immunoglobulins diluted 1:2000 in 5 mg/ml BSA in PBS-Tween 20. Substrate for peroxidase was orthophenylene diamine (5·5 mmol/l in 100 mmol/l citrate/ phosphate buffer pH 5·0, containing hydrogen peroxide at 10 mmol/l, 100 µl/well). The reaction was stopped after 30 min by addition of 1 mol/l sulphuric acid (50 µl). The absorbance at 490 nm was measured using an automated microplate reader (BIO-TEK Instrument Inc., Highland Park, VT, USA). For the initial solution phase assays, hybridoma-conditioned medium (100 µl) was incubated with 50 µl 125 I-LR 3 IGF-I in 250 µl RIA buffer (30 mmol/l NaH 2 PO 4 0·2 g/l protamine sulphate, 10 mmol/l disodium EDTA, 0·2 g/l NaN 3 , 0·5 ml/l Tween-20, pH 7·5) in polystyrene tubes. After 16 h at 4 C, tracer bound to mouse antibodies was precipitated by adding 20 µl of a suspension of cellulose coated with goat anti-mouse serum (Sac-Cel AA-SAC4, IDS, Boldon, UK) and incubating at room temperature for 30 min. Water (1 ml) was added and the tubes were centrifuged at 1000 g for 10 min at 4 C. Supernatants were aspirated and the radioactivity in the precipitates was measured in a gamma scintillation spectrometer. Two mouse IgG bound both solid phase LR 3 IGF-I and solution phase [ 125 I]-LR 3 IGF-I bound to mouse antibodies was precipitated with goat anti-mouse Sac-Cel as described above. [
125 I]-LR 3 IGF-I bound to rabbit antibodies was precipitated by addition of sheep anti-rabbit IgG and normal rabbit immunoglobulins . Radioactivity in the pellet was measured as above. Affinity constants were estimated by Scatchard analysis (Scatchard 1949 These were used to capture LR 3 IGF-I from 100 µl 10 ng/ ml LR 3 IGF-I in PBS-Tween 20 containing BSA at 5 mg/ ml during an incubation at 37 C for 2 h. Various concentrations of different rabbit antibodies including Nelson rabbit anti-LR 3 IGF-I immunoglobulins and GroPep rabbit anti-LR 3 IGF-I serum were then added in 100 µl and incubated for 2 h at 37 C. Plates were washed and wells were then incubated with peroxidase-conjugated goat antirabbit immunoglobulins followed by substrate solution as described above.
ELISA of LR 3 IGF-I in plasma
Plates were coated with mouse IgG 1A7-F5-E5 by adding 100 µl ascites fluid diluted 1/200 in coating buffer (above) to each well and incubating for 3 h at 37 C. After washing with PBS-Tween 20 as above, each well was blocked by addition of 100 µl 20 mg/ml BSA in PBSTween 20 and incubating overnight at 4 C. The plates were washed as above and 100 µl 5 mg/ml BSA in PBS-Tween 20 containing either 3% (vol/vol) of plasma from cows intravenously infused with LR 3 IGF-I at 12 µgh 1 kg 1 or LR 3 IGF-I standard (0 to 6 ng/ml with 3% of normal bovine plasma) were then added to triplicate wells, incubated for 2 h at 37 C and washed as above. Subsequently, 100 µl Nelson rabbit anti-LR 3 IGF-I immunoglobulins diluted 1:1000 in 5 mg/ml BSA in PBS-Tween 20 were added and incubated at 37 C for 2 h. After washing, LR 3 IGF-I-dependent immobilised rabbit immunoglobulins were measured with peroxidaseconjugated goat anti-rabbit immunoglobulins as described above. The specificity of the assay was assessed by comparing the responses produced by solutions of LR 3 IGF-I, IGF-I and IGF-II in 5 mg/ml BSA in PBS-Tween 20.
Recovery of LR 3 IGF-I in the ELISA
Recovery was determined by measuring the increase in activity in the LR 3 IGF-I ELISA produced by adding 100 µl 10 ng/ml LR 3 IGF-I assay standard to 30 µl of 11 different specimens of plasma from cows treated with this analog . These solutions were then diluted to a total volume of 1 ml with 5 mg/ml BSA in PBS-Tween 20 and triplicates of 100 µl were assayed. Intra-and interassay coefficients of variation were determined from the same analyses.
LR
3 IGF-I RIA LR 3 IGF-I in blood plasma was also measured by RIA (Conlon et al. 1995) . Plasma was acidified to pH 2·5 to dissociate complexes between IGFs and binding proteins which were then separated by size exclusion high performance liquid chromatography at pH 2·5 (Gargosky et al. 1990 , Carr et al. 1995 , Kind et al. 1995 . The eluate containing IGFs was neutralised with Tris-base and its LR 3 IGF-I content was measured by RIA. This step is necessary to completely remove IGFbinding proteins before LR 3 IGF-I RIA because although unextracted plasma from rats treated with LR 3 IGF-I (Tomas et al. 1992 (Tomas et al. , 1993a ) produces significant activity in this assay and the results correlate reasonably well with those obtained for the same specimens following size exclusion chromatography in acid (r=0·9, n=34, P<0·001), the RIA of unextracted plasma produces estimates of the concentration of LR 3 IGF-I that are 40% lower than those obtained by this assay when IGF-binding proteins have been completely removed by the chromatographic procedure (P C Owens, K J Quinn & S E Knowles, unpublished observations). The LR 3 IGF-I RIA was performed as described for IGF-I RIA (Carr et al. 1995 , Kind et al. 1995 except that LR 3 IGF-I was used as standard and for preparation of radio-iodinated ligand and GroPep rabbit anti-LR 3 IGF-I serum was used as primary antibody as reported previously (Conlon et al. 1995) .
Effects of IGF-binding proteins on the LR 3 IGF-I ELISA
The effects of IGF-binding proteins in plasma on the ELISA response to LR 3 IGF-I was investigated by adding LR 3 IGF-I-free plasma to LR 3 IGF-I before assay, by comparing ELISA measurements of the concentrations of LR 3 IGF-I in plasma from LR 3 IGF-I-treated animals with and without prior chromatographic removal of IGFbinding proteins and also by examining the effects of addition of pure IGF-binding protein-3 on the ELISA response to LR 3 IGF-I. The effect of blood plasma on this assay was assessed in two ways. First, LR 3 IGF-I assay standard at 5 ng/ml in different concentrations of normal bovine plasma was measured by ELISA. Secondly, LR 3 IGF-I standard in the range of 0·1 to 5 ng/ml with or without 10% (vol/vol) normal bovine plasma was also measured. To determine whether IGF-binding proteins in plasma affect the estimates of LR 3 IGF-I obtained by ELISA of diluted, unextracted plasma (i.e. assaying 100 µl 3% (vol/vol) plasma), the LR 3 IGF-I content of plasma from cows infused with LR 3 IGF-I was measured with and without size exclusion liquid chromatography at pH 2·5 prior to assay (Kind et al. 1995) . For this experiment, 0·2 ml 50% (vol/vol) plasma in mobile phase was chromatographed and the effluent containing free IGFs (i.e. unbound, dissociated from binding proteins) was collected in a volume of 2·25 ml. Triplicate aliquots were neutralised with Tris-base as above and 100 µl assayed for LR 3 IGF-I by ELISA. Unextracted aliquots of the same plasma specimens were diluted to 3% (vol/vol) in Trisneutralised chromatography mobile phase. In this assay, the LR 3 IGF-I standard was also prepared in neutralised mobile phase. Ovine IGF-binding protein-3 purified from plasma (Carr et al. 1994) was also added directly to the LR 3 IGF-I standard and its effect on the ELISA response was determined.
Results
In the presence of LR 3 IGF-I, plates coated with mouse IgG 1A7-F5-E5 were able to sequester rabbit polyclonal antibodies raised against either LR (Fig.1) . Scatchard analyses of the LR 3 IGF-I binding equilibrium data were also performed. For the solid phase antibody used in the LR 3 IGF-I ELISA (mouse IgG 1A7-F5-E5), the relative potencies of LR 3 IGF-I, R 3 IGF-I, IGF-I and long-IGF-I respectively were 1·0:0·78:0·028:0·005 on a mass basis and the equilibrium constant for association with LR 3 IGF-I was 7·3 10 9 l/mol (Fig. 1, upper panel) . Significant competition from IGF-II (not shown) could not be detected at concentrations as high as 1 µg/ml. For the solution phase antibody used in the LR 3 IGF-I ELISA (Nelson rabbit immunoglobulin), relative potencies on a mass basis of LR 3 IGF-I, R 3 IGF-I, IGF-I, long-IGF-I (Fig. 1, middle panel) and IGF-II (not shown) were 1·0:2·5:0·4:0·15:0·0005 respectively and the K a was 62 10 9 l/mol. For GroPep anti-LR 3 IGF-I serum, which is the primary antibody used in the RIA for LR 3 IGF-I (Conlon et al. 1995) and which does not bind to LR 3 IGF-I while the latter is complexed to mouse IgG 1A7-F5-E5, the relative potencies on a mass basis of LR 3 IGF-I, R 3 IGF-I, IGF-I and long-IGF-I respectively were 1·0:0·03:<0·001:0·002 (Fig. 1, lower panel) , while competition from IGF-II (0·01 to 1 µg/ml) could not be detected (not shown). The K a was 38 10 9 l/mol for GroPep anti-LR 3 IGF-I serum. In the LR 3 IGF-I ELISA, IGFs-I and -II have less than 0·01% of the activity of LR 3 IGF-I (Fig. 2) . A semi-linear LR 3 IGF-I response (Fig. 3, lower panel) was obtained over the range of 0·5 to 5 ng/ml or 55 to 550 pmol/l (i.e. 50 pg to 500 pg per 100 µl assayed) and plasma was found to slightly inhibit this response (Fig. 3) . Based on the increase in activity detected in the ELISA due to in vitro addition of the assay standard to plasma from cows treated with LR 3 IGF-I, the recovery was 91 11% (mean .., n=11). The intra-assay coefficient of variation (n=12 replicates) was 2·8% and the interassay coefficient of variation (n=6 assays) was 7·3% for a plasma sample obtained from an LR 3 IGF-I-treated cow whose average concentration of LR 3 IGF-I was 79 ng/ml of which 100 µl of a 3% (vol/vol) solution were measured.
The effect of endogenous plasma IGF-binding proteins on the measurement of LR 3 IGF-I in 100 µl 3% (vol/vol) plasma was estimated by ELISA measurement of LR 3 IGF-I in plasma from cows treated with this IGF analogue before (x) and after chromatography under acidic conditions that completely dissociate and separate IGFs from binding proteins (y). Regression analysis showed a slope that was not significantly different from unity and an intercept that was not significantly different from zero (y=0·99x+6·3, r=0·70, n=12, P<0·02) , considering the intra-assay coefficient of variation is 2·8%. The results for unextracted plasma were therefore not significantly different from those obtained for IGF-binding protein-free column eluates. Inclusion of pure ovine IGFBP-3 at 9 ng/well (equivalent to 3 µg/ml plasma) with LR 3 IGF-I at 300 pg/well (equivalent to 100 ng/ml plasma) also had no significant effect on the ELISA response (data not shown).
The concentrations of LR 3 IGF-I in plasma from cows treated with LR 3 IGF-I were measured using both ELISA of diluted unextracted plasma and LR 3 IGF-I RIA of binding protein-free extracts obtained by size exclusion chromatography of plasma at pH 2·5 (Fig. 1, bottom  panel) . The concentrations of LR 3 IGF-I measured by extracted RIA were lower than those measured by unextracted ELISA (Fig. 4) but there was a similar trend of LR 3 IGF-I concentration over time detected by both methods. Plasma levels of LR 3 IGF-I were maximal after 7 h intravenous infusion at 12 µgkg 1 h 1 at 95·7 5·5 ng/ml (mean ..., n=6) by ELISA and at 71·7 3·5 ng/ml by RIA. Plasma from placebo-treated cows contained undetectable levels of LR 3 IGF-I by both assays. There was a positive correlation between the results of the two LR 3 IGF-I assays (r=0·54, n=48, P<0·001).
Discussion
The abilities of mouse IgG 1A7-F5-E5 and Nelson rabbit immunoglobulins to simultaneously bind to LR 3 IGF-I indicate that these antibodies associate with different and remote epitopes on the LR 3 IGF-I protein. The inability of GroPep rabbit anti-LR 3 IGF-I serum and mouse IgG 1A7-F5-E5 to simultaneously bind LR 3 IGF-I indicate that these antibodies bind to similar or adjacent epitopes. These conclusions are consistent with the specificities of these antibodies. The arginine 3 substitution markedly increases the affinities of IGF-I and long-IGF-I for both mouse IgG 1A7-F5-E5 and GroPep rabbit anti-LR 3 IGF-I Studies of the effects of in vitro incubations of LR 3 IGF-I and normal bovine blood plasma showed that the ELISA detects LR 3 IGF-I in the presence of plasma, although high concentrations of plasma (>5% vol/vol) slightly reduce the response. However, the high assay sensitivity combined with the relatively high circulating concentrations achieved by intravenous infusion of LR 3 IGF-I at a pharmacologically active dose rate permitted a 33-fold dilution of the test plasma before analysis by ELISA. At this concentration (3% plasma, vol/vol) the effect of LR 3 IGF-I-free plasma on the response to LR 3 IGF-I was very small. This effect does not appear to be due to plasma IGF-binding proteins because elimination of IGF-binding proteins from specimens tested in the ELISA by prior acidic size exclusion chromatography had no significant effect on the ELISA measurements and addition of pure IGF-binding protein-3 had no effect on the ELISA response to LR 3 IGF-I. None-the-less, standards were routinely prepared in 3% normal bovine plasma for these measurements.
An advantage of the new ELISA over the established RIA is the elimination of the need for an extraction step to remove IGF-binding proteins from the specimens to be assayed. IGF-binding protein contamination is a major problem in all IGFs-I and -II RIAs (Hintz & Liu 1977 , Powell et al. 1986 , Daughaday et al. 1987 , Breier et al. 1991 , Crawford et al. 1992 . In principle, IGF-binding proteins cause different problems in competitive tracer binding systems such as those used for RIA than those caused in noncompetitive ELISA systems. Because RIA procedures depend on competition between fixed amounts of labelled antigen (tracer) and variable amounts of unlabelled antigen for binding to fixed amounts of antibody, additional reactions that affect binding to antibody of either tracer or unlabelled antigen can cause estimation errors in these analyses. IGF-binding proteins in RIA procedures can bind to either radiolabelled or unlabelled IGFs and this can inhibit binding of these ligands to the antibody. Inhibition of labelled antigen (tracer) binding to antibody due to formation of complexes between binding proteins originating in the test specimens and tracer added to the incubation with primary antibody will produce overestimation artefacts in RIA procedures. Conversely, inhibition of unlabelled antigen (i.e. the target test material) binding to antibody due to formation of complexes between binding proteins and unlabelled IGFs can produce underestimation errors. Artefacts of both types have been observed for IGF-I RIAs, although underestimation errors are most common. When the LR 3 IGF-I RIA was used to measure LR 3 IGF-I in plasma from rats treated for 1 week with this IGF analog (Tomas et al. 1992 (Tomas et al. , 1993a , the results obtained for diluted unextracted plasma were found to correlate reasonably well (r=0·9, P<0·001) with those obtained for the same specimens when IGFbinding proteins were completely removed from the assay system by prior size exclusion chromatography of plasma under conditions that dissociate IGFs from IGF-binding proteins. However, the values obtained by RIA of unextracted plasma were consistently about 40% lower than those obtained by the same LR 3 IGF-I RIA of the same plasma samples after acidic size exclusion chromatography. This indicates that some of the unlabelled LR 3 IGF-I has formed complexes with IGF-binding proteins in the primary RIA incubation, which has reduced the ability of LR 3 IGF-I to react with the primary antibody and thus reduced its ability to inhibit tracer binding to this antibody. We have never observed overestimation errors in the LR 3 IGF-I RIA, indicating that [ 125 I]-iodo-LR 3 IGF-I, unlike unlabelled LR 3 IGF-I, does not significantly associate with IGF-binding proteins under the same assay conditions. This would occur if [
125 I]-iodo-LR 3 IGF-I has a lower affinity than unlabelled LR 3 IGF-I for IGF-binding proteins. This is possible because iodination of IGFs does alter their binding characteristics. For example, iodination of IGF-I has been shown to reduce the affinity of IGF-I for binding to IGF-binding protein-3 from pregnant human serum (Suikkari & Baxter 1991) and radio-iodination of IGF-II abolishes its ability to bind to Type 1 IGF receptors on cultured rat myoblasts (Francis et al. 1989 ). In the LR 3 IGF-I ELISA, the presence of IGF-binding proteins in specimens added to the assay did not reduce the ability of LR 3 IGF-I to form ternary complexes with the assay antibodies. This has also been observed with IGF-I ELISA (Khosravi et al. 1996) . This difference in performance of the RIA and the ELISA is not due to the differences in affinities of different antibodies for LR 3 IGF-I because the GroPep rabbit antiserum used in the RIA has a higher affinity (3·8 10 10 l/mol) than the solid phase monoclonal IgG (0·73 10 10 l/mol) used in the ELISA. It is most likely due to the differences in the concentrations of antibodies to which the antigen is exposed in the two systems. In the RIA, the antiserum is highly diluted to achieve maximum sensitivity, so that the primary antibody can be almost completely saturated (i.e. no radioligand bound) by the highest concentration of unlabelled standard and test ligand. Conversely in the ELISA, maximum sensitivity is achieved at the highest possible concentrations of antibodies, which are added in excess (Khosravi et al. 1996) .
In conclusion, we have developed a fast, sensitive, specific non-isotopic assay for an analog of IGF-I that detects biologically active concentrations of this growth factor in animals. The availability of this ELISA will facilitate studies of the pharmacological actions of this commercially available growth factor, which should assist studies of IGF action in vivo.
